LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

Home・Stock List・Johnson and Johnson

Johnson and Johnson

Closed

Sector Healthcare

160.55 0.48

Buy Sell

Overview

Share price change

24h

Current

Min

159.38

Max

161.54

Key metrics
By Trading Economics
Income	-794M 3.3B
Sales	-15M 21B
P/E Sector Avg	30.42 79.786
EPS	2.71
Profit margin	15.225
Employees	131,900
EBITDA	-776M 5.7B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+7.78 upside

Dividends
By Dow Jones
Next Earnings	15 Oct 2024
Next Dividend date	10 Sept 2024
Next Ex Dividend date	27 Aug 2024

Market Stats
By TradingEconomics
Market Cap	9.6B 362B
Previous open	160.07
Previous close	160.55

News Sentiment

By Acuity

57%

43%

300 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

156.58 / N/A Support & Resistance

Johnson and Johnson Chart

Related News

17 Jul 2024, 14:14 UTC

Earnings

Trending: Johnson & Johnson Beats 2Q Sales Guidance

17 Jul 2024, 11:24 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

J&J Lifts Sales View But Lowers Earnings Outlook -- Market Talk

17 Jul 2024, 10:43 UTC

Earnings

Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance -- IBD

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson: MedTech Operational Sales Growth Expected to Accelerate in 2H >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Cuts 2024 View To Adj EPS $9.97-Adj EPS $10.07 Vs Prior View $10.57-$10.72 >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Backs 2024 Adjusted Operational Sales Growth View of 5.5%-6% >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson: 2Q MedTech Worldwide Operational Sales Growth Was Driven Primarily by Electrophysiology Products and Abiomed in Cardiovascular, and Wound Closure Products in General Surgery >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Backs 2024 Sales $88.0B-$88.4B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $10.00-$10.10 Vs Prior View $10.60-$10.75 >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson: 2Q Innovative Medicine Worldwide Operational Sales, Excluding Covid Vaccine, Grew 8.8% >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Updating 2024 Guidance to Reflect Improved Performance and Impact for Recent Acquisitions of Shockwave Medical, Proteologix and NM26 Bispecific Antibody >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson Raises 2024 Operational Sales View to $89.2B-$89.6B Vs Prior View $88.7B-$89.1B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Worldwide MedTech Sales $7.96B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson: Including Covid Vaccine, 2Q Innovative Medicine Worldwide Operational Sales Grew 7.8% >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson: 2Q MedTech Worldwide Operational Sales Grew 4.4%, With Acquisitions and Divestitures Postively Affecting Growth by 0.4% >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q International Sales $9.88B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q EPS $1.93 >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Sales $22.45B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $14.49B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q U.S. Sales $12.57B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Orthopaedics Sales $2.31B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Adj EPS $2.82 >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q U.S. Sales $12.57B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q International Sales $9.88B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $14.49B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q EPS $1.93 >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Adj EPS $2.82 >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Net $4.69B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Sales $22.4B >JNJ

17 Jul 2024, 10:20 UTC

Earnings

Johnson & Johnson 2Q Worldwide MedTech Sales $7.96B >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

7.78% upside

12 Months Forecast

Average 173.14 USD 7.78%

High 215 USD

Low 150 USD

Based on 15 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to Johnson and Johnson - Dist in the past 3 months.

Technical Score

By Trading Central

156.58 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

300 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.